Company Update (NYSE:MRK): Merck Announces FDA Acceptance for Review of MK-3475 Biologics License Application for Advanced Melanoma

[Business Wire] – Merck , known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application for MK-3475, . . . → Read More: Company Update (NYSE:MRK): Merck Announces FDA Acceptance for Review of MK-3475 Biologics License Application for Advanced Melanoma Similar Articles: Market Update: Merck & Co Inc (NYSE:MRK) – Merck to Hold Investor Briefing at Boston Research Facility Company Update (NYSE:MRK): Merck to Hold First-Quarter 2014 Sales and Earnings Conference Call on April 29 Merck & Co. Inc. (NYSE:MRK) – 8:31 am Merck initiates rolling submission of U.S. Biologics License Application for MK-3475, an investigational Anti-PD-1 Immunotherapy, in patients with advanced melanoma; expects to complete application in 1H14